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ORIGINAL ARTICLE
Identification of IL11RA and MELK amplification in gastric 
cancer by comprehensive genomic profiling of gastric 
cancer cell lines
Basic Study
Danielle Queiroz Calcagno, Sylvia Santomi Takeno, Carolina Oliveira Gigek, Mariana Ferreira Leal, 
Fernanda Wisnieski, Elizabeth Suchi Chen, Taíssa Maíra Thomaz Araújo, Eleonidas Moura Lima, 
Maria Isabel Melaragno, Samia Demachki, Paulo Pimentel Assumpção, Rommel Rodriguez Burbano, 
Marília Cardoso Smith
Abstract
AIM
To identify common copy number alterations on gastric 
cancer cell lines.
METHODS
Four gastric cancer cell lines (ACP02, ACP03, AGP01 
and PG100) underwent chromosomal comparative 
genome hybridization and array comparative genome 
hybridization. We also confirmed the results by 
fluorescence in situ  hybridization analysis using the 
bacterial artificial chromosome clone and quantitative 
real time PCR analysis.
RESULTS
The amplification of 9p13.3 was detected in all cell 
lines by both methodologies. An increase in the copy 
number of 9p13.3 was also confirmed by fluorescence 
in situ  hybridization analysis. Moreover, the interleukin 
11 receptor alpha (IL11RA) and maternal embryonic 
leucine zipper kinase (MELK) genes, which are present 
in the 9p13.3 amplicon, revealed gains of the MELK 
gene in all the cell lines studied. Additionally, a gain in 
the copy number of IL11RA and MELK was observed in 
19.1% (13/68) and 55.9% (38/68) of primary gastric 
adenocarcinoma samples, respectively. 
CONCLUSION
The characterization of a small gain region at 9p13.3 
in gastric cancer cell lines and primary gastric 
adenocarcinoma samples has revealed MELK  as a 
candidate target gene that is possibly related to the 
development of gastric cancer. 
Key words: IL11RA; Gastric cancer; Genomic profiling; 
MELK; 9p13.3 
© The Author(s) 2016. Published by Baishideng Publishing 
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Core tip: While the presence of alterations in the DNA copy 
number is one of the key hallmarks of carcinogenesis, in 
gastric cancer, the chromosomal regions with frequent 
gain and loss are still poorly defined. Array comparative 
genome hybridization is a high resolution tool that allows 
the simultaneous detection of sub-microscopic copy 
number changes across the genome. The characterization 
of a small gain or loss region in gastric cancer cell lines 
and primary gastric adenocarcinoma samples could reveal 
a candidate target gene that may possibly be linked to the 
development of gastric cancer. 
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INTRODUCTION
Gastric cancer (GC) remains a major public health issues, 
as it is the fifth most common malignancy and the third 
leading cause of cancer death in both sexes worldwide[1]. 
The most common type of GC is adenocarcinoma, 
which can be further categorized into two main types, 
intestinal type and diffuse type, which are biologically 
different with distinct clinical and epidemiological 
profiles[2]. The difference in the clinicopathological 
characteristics between the histological types of gastric 
cancer indicate that gastric tumor development occurs 
through the progressive accumulation of distinct genetic 
alterations[2-5]. Thus, the characterization of these 
genomic abnormalities in gastric cancer may help to 
clarify the molecular pathogenesis of the disease and 
may unveil genetic markers of progression and for 
predicting treatment response or survival.
Genomic instability with frequent DNA copy number 
variations (CNVs) is one of the key hallmarks of 
gastric carcinogenesis[6]. Tumor progression seems to 
depend on the successive acquisition of chromosomal 
aberrations, leading to gains or losses of parts of the 
genome. However, there is no clear agreement on the 
genetic changes underlying gastric carcinogenesis. 
In the last decades, chromosomal comparative 
genome hybridization (cCGH) and array CGH (aCGH) 
analyses of gastric tumors and gastric cell lines have 
revealed recurrent DNA CNVs[7-11]. Using cCGH, 
Burbano et al[3] showed that the copy number gain 
of 8q24.1, the locus containing the MYC oncogene, is 
a frequent alteration in GC. Further investigations by 
our group demonstrated that MYC amplification is a 
common finding in preneoplastic gastric lesions and 
tumors[4,5,12-15]. 
Moreover, Takeno et al[10] stated that diffuse-
type GC shows a complex pattern of chromosomal 
alterations, especially chromosome region losses. 
Recently, Liang et al[16] suggested that the detection 
of DNA CNVs from tissue or blood samples may be 
a useful tool for guiding individualized treatment 
strategies and for identifying new drug targets in 
patients with GC. 
In the current study, we analyzed the chromosomal 
abnormalities of four GC cell lines by cCGH and aCGH. 
The occurrence of the amplification of chromosomal 
region 9p13 in GC cell lines was validated by 
fluorescence in situ hybridization (FISH) and confirmed 
in primary gastric adenocarcinoma samples by 
quantitative polymerase chain reaction (qPCR). Among 
the genes within the 9p13 region, we chose two genes 
for validation in primary GC samples, interleukin 11 
receptor alpha (IL11RA) and maternal embryonic 
leucine zipper kinase (MELK).
MATERIALS AND METHODS
Gastric cancer cell lines 
The ACP02, ACP03 and AGP01 gastric adenocarcinoma 
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cell lines, which were previously established and 
characterized by our research group, were used in 
the present study[17,18]. Additionally, we used the GC 
cell line, PG100, obtained from the Rio de Janeiro Cell 
Bank (Rio de Janeiro, RJ, Brazil), which was previously 
characterized cytogenetically by our group[19]. All cell 
lines were cultured according to Lima et al[20].
Primary gastric cancer samples
Quantitative gene copy number measurements were 
performed on 68 primary gastric adenocarcinoma 
samples that were obtained from patients who 
underwent surgery resection in João de Barros Barreto 
University Hospital (HUJBB), Belém, Pará, Brazil. In 
Pará, Brazil, the human population is composed of 
interethnic crosses between three main origin groups, 
European (mainly represented by Portuguese), Africans, 
and Amerindians[21].
All the patients had negative histories of exposure 
to either chemotherapy or radiotherapy before surgery, 
and there were no other diagnosed cancers. Signed 
informed consent, with the approval of the ethics 
committee of HUJBB, was obtained from all patients 
prior to the collection of samples.
DNA isolation
DNA from the GC cells lines and gastric tumors were 
isolated using the QiAmp DNA isolation kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
recommended protocol. DNA concentration and purity 
were evaluated by Nanodrop (NanoDrop Techno-
logies, Houston, TX, United States) and agarose 
gel electrophoresis. All DNA samples used had an 
A260/280 ratio of 1.8-2.0 and an A260/A230 ratio of 
> 1.5 and were visualized as a high molecular weight 
band on an agarose gel.  
cCGH
DNA samples from GC cell lines were labeled using 
the CGH Nick Translation Kit (Abbott Laboratories, IL, 
United States) with Control DNA (Promega, Madison, 
United States) according to the manufacturer’s 
instructions. Hybridization was performed with CGH 
Metaphase Target Slides (Abbott Laboratories, Illinois, 
United States), following the manufacturer’s protocols. 
The slides were analyzed by Corel Photo-Paint - 
Version 5.00 - Isis Zeiss® software, using an Axioskop 
Zeiss microscope (Carl Zeiss Inc. Canada, Don Mills, 
ON, Canada) equipped with an epi-illuminator and 
fluorochrome-specific optical filters. 
The three-color images with red, green, and blue 
were acquired from 15 metaphases. Chromosome 
imbalances were detected on the basis of the deviation 
of the fluorescence ratio profile from the balanced 
value (FITC:rhodamine = 1). For each chromosome, 
the final ratio values were prepared from the mean 
values of at least ten chromosome homologues from 
separate metaphase spreads. The CGH results were 
plotted as a series of green to red ratio profiles.
aCGH
To evaluate the complete genome of all the four cell 
lines studied, high density microarray analysis was 
performed using the AffymetrixR CytoScan™ HD 
Array platform (Affymetrix, Santa Clara, CA, United 
States). First, genomic DNA was digested by the NspI 
restriction enzyme, and the digested samples were 
ligated using the NspI adaptor. The fragments were 
amplified by PCR and run on a 2% agarose gel to verify 
that the PCR product size distribution was between 
150 bp and 2000 bp. After PCR product purification 
and dilution, we performed the quantification of each 
sample using a NanodropR 1000 Spectophotometer 
(NanoDrop Technologies, Houston, TX, United States). 
The average purification yield for each sample was ≥ 
3.0 μg/μL.
The purified samples were then fragmented using 
DNAse I enzyme, and the products were run on a 4% 
agarose gel to verify that the majority of fragments 
had a size distribution between 25 and 125 bp.
Labeling was performed using terminal de-
oxynucleotidyl transferase enzyme, which adds 
biotinylated nucleotides at the 3’ end of fragmented 
samples.
During the hybridization step, each sample was 
hybridized onto a CytoScan® HD Array (Affymetrix, 
Santa Clara, CA, United States) and placed in a 
GeneChip® Hybridization Oven 640 (Affymetrix, Santa 
Clara, CA, United States) at 50 ℃ and 60 rpm for 16 
to 18 h. The processes prior to scanning of arrays, 
washing and staining, were carried out at a Fluidics 
Station 450 (Affymetrix, Santa Clara, CA, United 
States). The arrays were scanned using GeneChip® 
Scanner 3000 7G (Affymetrix, Santa Clara, CA, United 
States).
The copy number was deduced from the weighted 
log2 ratio and the aberration type was identified and 
confirmed using allelic plots.
FISH
FISH was performed on nuclei and metaphase 
spreads of the cell lines, ACP02, ACP03 and AGP01. 
Metaphase spreads of lymphocytes from a healthy 
donor were used as a control. The bacterial artifi-
cial chromosome (BAC) clone, RP11-165H19, was 
obtained from BAC/PAC Resources (http://bacpac.
chori.org/). Bacterial cultures and DNA isolation was 
performed using Qiagen Plasmid Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. 
Alu-PCR products of the BAC were used as probes and 
were biotinylated using nick translation, as described 
previously[22].
qPCR
For the validation of 9p13 amplification, we evalua-
ted the copy number of two genes within this locus, 
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χ 2 test or two-tailed Fisher’s exact test for categorical 
variables. All statistical analyses were performed with 
the statistical package SPSS for Windows (V.17.0, 
SPSS Inc, Chicago, IL, United States). P values of ≤ 
0.05 were considered significant.
RESULTS
Recurrent regions of alterations 
The ACP02, ACP03, AGP01 and PG100 cell lines 
showed multiple gains and losses by cCGH and aCGH. 
Most chromosomal aberrations detected in these cell 
lines by cCGH were confirmed by aCGH (Table 1), 
although aCGH analysis enabled the identification of 
many additional chromosomal gains and losses. On 
the other hand, the gain of 16p21-p23 in ACP03 and 
the gains of 6p11-p12, 12p11.1 and 18p11.2-p11.3 in 
AGP01 were detected only by cCGH.
Notably, the gain of chromosome region 9p13 was 
common in all cell lines and as such, this locus was 
selected for further investigation.
IL11RA and MELK. For this, we used the same DNA 
samples from GC cell lines that were used for cCGH 
and aCGH and from GC tissues. qPCR was performed 
using the FAM/MGB-labeled TaqMan probes (Life 
Technologies, Foster City, CA, USA) for IL11RA 
(Hs01842695_cn) or MELK (Hs05076287_cn). VIC/
TAMRA-labeled TaqManCopy Number Reference Assay 
RNAse P (#4403326; Life Technologies, Foster City, 
CA, United States) was used as an internal control. 
All the real-time qPCR reactions were performed in 
quadruplicate with gDNA using a 7500 Fast Real-Time 
PCR system (Life Technologies, Foster City, CA, United 
States) as described previously[13]. The copy number 
of each sample was estimated by CNV analysis using 
Copy Caller Software V1.0 (Life Technologies, Foster 
City, CA, United States). Known Human Genomic DNA, 
G1471 and G1521 (Promega, Madison, United States), 
were used for calibration.
Statistical analysis
The data on clinical features were compared by the 
Table 1  Overview of detected chromosomal aberrations by chromosomal comparative genome hybridization and array comparative 
genome hybridization on gastric cancer cell lines
Cell line cCGH aCGH
ACP02 +8p21-pter, +8q24, +9p12-p22, +9q21.1-q21.3, 
+15q11.1-q14, +16p, +16q, +17p11, +17q11.2, 
+17q23, +22q11.1-q12.3
+1p13.2, +1p21.3, +1q21.2, +1q21.3, +2p11.2, +4p12, +4p13, +4q12, +5q12.1, +7q11.22, 
+7q11.23, +8p11.23, +8p21.3, +8q24.11, +8q24.22, -8q24.22, +8q24.23, +8q24.3, +9p13.2, 
+9p13.3, +9p11.3, +9q21.12, +10p11.22, +10p12.1, +10p12.31, +10p13, +10p14, +10q11.21, 
-11p11.12, +11p11.2, , -11q12.1, -11q12.2, -11q12.3, +12q12-q15, +13q12.11, +14q11.2, 
+15q11.2, +15q12, +15q14, +15q15.3, +15q24.1, +15q25.1, +15q26.1, +16p11.2, +16p12.3, 
+16q11.2, +16q13, +16q21, +16q22.1, +17p11.2, +17q11.2, +17q23.1, +18q11.2, +19q13.11, 
+20p11.1, +20p11.23, +20p12.2, +20q11.21, +20q11.23, +22q11.21,+ 22q11.23, +22q12.2, 
+22q12.3
ACP03 +4p15.1-pter, +6p22.3-p24, +6q25.1,q26, +8p22-
pter, -8q11.1-q11.2, +9p12-p22, +10p12-p14, 
-11p11.1, -11q12, +15q11.1-q15, +15q23-q26.1, 
+16p12-p13.1, +16p21-p23, +22q11.1-q12.1
+1p13.2, +1p13.3, +1p21.3, +1q21.1, +1q21.2, 1q21.3, +2p12, +4p12, +4p14-p13, +4p15.1, 
+5q12.1, +6p24.2, +7q11.21, +7q11.22, +7q11.23, +8p11.21, +8p11.23-p11.22, +8p21.2, 
+8p21.3, -8q11.21, +8q24.11, -8q24.12, +8q24.13, +8q24.21, +8q24.22, -8q24.22, +8q24.23, 
+8q24.3, +9p13.2, +9p13.3, +9q21.13, +9p23, +10p11.21, +10p11.22, +10p12.1, +10p12.2, 
+10p12.31, +10p12.33, +10p13, +10p14, +10q11.21, -11p11.12, +11q11.2, -11q12.1-q12.2, 
-11q12.3, +12q12-q15, +14q11.2, +14q13.2, +15q11.2, +15q12, +15q13.1, +15q14, +15q24.1, 
+15q25.1, +15q25.2, +15q26.1, +16p11.2, +16p12.3, +16q11.2, +16q12.1, +16q12.2, +16q21, 
+16q22.1, +17p11.2, +17q11.2, +17q23.1, +18q11.2, +18q12.1, +19q13.11, +20p11.1, 
+20p11.23, +20p12.2, +20q11.21, +20q11.22, +20q11.23, +22q11.21, +22q11.23, +22q12.2, 
+22q12.3
AGP01 +1p13-21, +1q12-q21.3, +2p11.2-p12, 
+4p11-p12, +4q12-q13.1, +5p11-p12, 
+5q11.2-q12, +6p11-p12, +6q12-q16.1, 
+7q11.1-q11.2, +9p12-p13, +9q13-q21.3, 
+10p11.2-p12.3, +10q11.1-q21.1, +11p11-p11.2, 
+12p11.1, +12q12, +13q11-q12, +14q11.1-q13, 
+15q11-q14, +16p11.2, +16q12, +17p11.2, 
+17q11.2, +18p11.2-p11.3, +18q11-q12, 
+19q12-q13.1, +20p11.2-p12, +20q11.1-q11.2 
+1p13.3, +1p21.3, +1q21.2, +1q21.3, +2p11.2, +2p12, +4p12, +4p14-p13, +5p12, +5q12.1, 
+6p24.2, +6q13, +7q11.21, +7q11.22, +7q11.23, +8p11.21, +8p11.23-p11.22, +8p21.3, 
-8q11.21, +8q24.11, -8q24.12, +8q24.21, +8q24.22, +8q24.23, +8q24.3, +9p13.2, +9p13.3, 
+9p22.3, +9q21.12, +9q21.13, +10p11.22, +10p12.1, +10p12.31, +10p13, +10p14, +10q11.21,   
-11p11.12, +11p11.2, -11q12.1, -11q12.2, -11q12.3, +12q12-q15, +13q12.11, +14q11.2, +15q12, 
+15q14, +15q15.1, +15q15.3, +15q24.1, +15q25.1, +15q25.2, +15q25.3, +15q26.1, +16p11.2, 
+16p12.3, +16q11.2, +16q12.1, +16q13, +16q21, +16q22.1, +17p11.2, +17q11.2, +17q23.1, 
+18q11.2, +19q13.11, +20p11.21, +20p11.1, +20p11.23, +20p12.2, 20q11.21, +20q11.23, 
+22q11.21, +22q11.23, +22q12.2, +22q12.3
PG100 +9p12-p23 +1p13.2, +1p13.3, +1p21.3, +1q21.1, +1q21.2, +1q21.3, +2p11.2, +4p15.1, +6q13, +7q11.21, 
+7q11.22, +7q11.23, +8p11.21, +8p11.23-p11.22, +8p21.2, +8p21.3, -8q11.21, +8q24.11, 
+8q24.13, +8q24.22, -8q24.22, +8q24.23, +8q24.3, +9p13.2, +9p13.3, +9p22.3, +9q21.12, 
+9q21.13, +10p11.22, +10p12.1, +10p12.2, +10p12.31, +10p14, +10q11.21, +11p11.2, 
-11q12.1, -11q12.2, -11q12.3, +12q12-q15, +13q12.11, +14q11.2, +15q11.2, +15q12, +15q14, 
+15q15.1, +15q15.3, +15q24.1, +15q25.2, +15q25.3, +15q26.1, +16p11.2, +16p12.3, +16q11.2, 
+16q12.1, +16q21, +16q22.1, +17p11.2, +17q11.2, +17q23.1, +18q11.2, +19q13.11, +20p11.1, 
+20p11.23, +20p12.2, +20q11.21, +20q11.23, +22q11.21, +22q11.23, +22q12.1-q12.2, 
+22q12.2, +22q12.3
cCGH: Chromosomal comparative genome hybridization; aCGH: Array comparative genome hybridization.
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Validation of the amplified pericentromeric region, 9p13 
The presence of the 9p13 amplification in the GC cell 
lines was confirmed by metaphase FISH using a BAC 
clone (Figure 1). We observed signal gain in all cell 
lines, and only ACP02 showed high amplification of this 
region (Table 2). 
Based on gene location and annotated gene 
function, we selected the MELK and IL11RA genes for 
validation in GC cell lines and in 68 primary gastric 
adenocarcinoma by qPCR. We detected two copies of 
IL11RA and three copies of MELK in all GC cell lines. 
By analyzing the CNV of these two genes in gastric 
tumors, we observed that 19.1% (13/68) and 55.9% 
(38/68) of gastric tumors had ≥ 3 copies of IL11RA 
and MELK, respectively. No association was found 
between the clinicopathological characteristics of 
patients and the number of copies of the studied genes 
(Table 3).
DISCUSSION
aCGH is a high resolution tool that allows the simul-
taneous detection of sub-microscopic copy number 
changes across the genome, thus overcoming the 
several limitations of cCHG[23]. In this study, most of 
the copy number changes observed in ACP02, ACP03, 
AGP01 and PG100 by cCGH were confirmed by aCGH. 
ACP02, ACP03 and AGP01 are gastric adenocarcinoma 
cell lines from diffuse and intestinal types and can-
cerous ascitic fluid and were previously established 
and characterized by our research group[17,18], while 
PG100 is a commercially available primary gastric 
adenocarcinoma cell line[19]. Furthermore, aCGH 
analysis enabled the identification of many additional 
chromosomal gains and losses. On the other hand, the 
gain of the 16p21-p23 region in ACP03 and the gains 
of the 6p11-p12, 12p11.1 and 18p11.2-p11.3 regions 
in AGP01 were only detected by cCGH. This may be 
due to technical reasons, as cCGH is more sensitive 
than aCGH for detecting large chromosome regions, as 
previously discussed by Kamradt et al[24]. 
When comparing the GC cell lines, only a few 
differences in cytogenetic composition were found 
by cCGH and aCGH. The gain on 9p13.3 was found 
in all cell lines, and the presence of this amplicon in 
these gastric cell lines was confirmed by metaphase 
FISH, using a BAC clone for the amplified region. It is 
noteworthy that high levels of this amplification were 
only found in ACP02. 
Genetic alterations in the short arm of chromo-
some 9 are commonly observed in different cancer 
types[25]. In GC, losses of 9p have been frequently 
described[26-29]. Fan et al[29] (2012) observed a 
homozygous deletion at 9p21, which encompasses the 
P16INK4A tumor suppressor gene, in 11% (8/72) of 
the gastric tumors studied. To our knowledge, this is 
Table 2  Number of copies of 9q13 locus by FISH analysis in gastric cancer cell lines  n  (%)
Cell line 0 signal 1 signal 2 signals 3 signals 4 signals ≥ 5 signals 
ACP02  12 (6.0) 26 (13.0) 112 (56.0) 25 (12.5)   22 (11.0) 3 (1.5)
ACP03    22 (11.0) 40 (20.0)   99 (49.5) 22 (11.0)   6 (3.0) 1 (0.5)
AGP01  19 (9.5) 45 (22.5)   99 (49.5) 27 (13.5) 10 (5.0) -
PG100  18 (9.0) 55 (27.5)   87 (43.5) 32 (16.0)   7 (3.5) 1 (0.5)
Control    34 (17.0) 68 (34.0)   97 (48.5) 1 (0.5) - -
Table 3  MELK and IL11RA gene copy number and clinicopathological features of 68 gastric cancer patients
MELK IL11RA
2 copies (n  = 38) ≥ 3 copies (n  = 30) P  value 2 copies (n  = 55) ≥ 3 copies (n  = 13) P  value
Age (yr) (mean ± SD)
   > 50 (64.5 ± 6.9) 23 25 0.0748 39   9 0.7461
   ≤ 50 (42.5 ± 5.2) 15   5 16   4
Gender
   Male 23 21 0.5781 34   9 0.7544
   Female 15   9 21   4
Histopathology
   Intestinal 23 20 0.7886 32 11 0.1110
   Diffuse 15 10 23   2
Depth of tumor invasion
   pT1-pT2 10 11 0.5137 18   3 0.4076
   pT3-pT4 28 19 36 10
Lymph node metastasis
   Absent 10   7 1.0000 11   6 0.1091
   Present 28 23 44   7
Stage
   Ⅰ-Ⅱ 25 17 0.6049 33   9 0.7525
   Ⅲ-Ⅳ 13 13 22   4
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the first study that describes gains at 9p in GC.
Amplifications on 9p have been reported in eso-
phageal cancer[30], lung sarcomatoid carcinoma[31] 
and breast cancer[32]. Towle et al[33] found that 16.6% 
(36/217) of the cell lines carried regions of genomic 
gain spanning part of chromosome 9p13. Additionally, 
1.8% (4/217) harbored high-level DNA amplification 
of this region, including a ductal breast carcinoma 
line (B0T-474), a tongue squamous cell carcinoma 
line (SCC-9), a melanoma line (WM-115), and an 
osteosarcoma line (MG-63). 
Because this region harbors several tumor-related 
genes, several studies in the literature have correlated 
gene copy number alterations of 9p13 with cancer[24,34]. 
Sarhadi et al[34] observed that the gain of chromosome 
9p13 encompasses many genes, such as KIAA1161, 
C9orf24, C9orf25, DNAI1, ENHO, CNTFR, LOC415056, 
C9orf23, DCTN3, ARID3C, SIGMAR1, GALT, IL11RA, 
CCL27, CCL19, CCL21 and FAM205A, in different types 
of cancer.
In this study, we selected the IL11RA and MELK 
genes to validate this amplification region in GC cell 
lines and primary gastric adenocarcinoma. The results 
showed an increase in the copy number of the MELK 
gene in ACP02, ACP03, AGP01 and PG100. Moreover, 
19.1% (13/68) and 55.9% (38/68) of gastric tumors 
showed ≥ 3 copies of IL11RA and MELK, respectively. 
Kamradt et al[24] analyzed a small amplicon at 
9p13.3 in prostate cancer cell lines and validated 
IL11RA copy number gain in 75% (15/20) of prostate 
tumors. In addition, it has been demonstrated that 
IL11RA is overexpressed in GC, colon cancer, breast 
cancer, prostate cancer and osteosarcoma[35-41]. IL11RA 
encodes a specific receptor for IL11, and the IL11/
IL11RA signaling pathway is involved in the regulation 
of several biological activities, such as adipogenesis, 
osteoclastogenesis, neurogenesis, and megakaryocyte 
maturation and platelet production[42,43].
With regard to MELK, the other gene that was 
selected for validation, this study describes, for the 
first time, that the copy number gain of the MELK gene 
occurs in cancer. To our knowledge, only one previous 
study on astrocytoma samples has investigated MELK 
amplification, and they did not find any MELK copy 
number gain[44]. 
MELK is a highly conserved serine/threonine kinase 
that was first found to be expressed in a wide range 
of early embryonic cellular stages, and as a result, it 
has been implicated in embryogenesis and cell cycle 
control[45]. Additionally, several studies have identi-
fied MELK overexpression in stem cell populations 
and several human cancers, including aggressive 
astrocytoma, breast cancer, prostate cancer, melanoma 
and GC[44-49]. 
Preclinical studies have suggested MELK as a po-
tential therapeutic target for multiple cancers. Since 
then, novel therapeutics that selectively inhibit MELK 
have been developed, such as OTSSP167, which is 
currently in a Phase I trial for patients with solid tumors 
and who have not responded to treatment[45,50-53].
Li et al[54] observed MELK overexpression more 
frequently in GC lesions than in the corresponding 
noncancerous mucosa and that higher MELK levels 
were associated with lymph node involvement, distant 
metastasis, and poor prognosis in patients with GC. 
In addition, these authors demonstrated that reducing 
MELK expression or inhibiting its kinase activity 
resulted in growth inhibition, G2/M arrest, apoptosis 
and the suppression of the invasive capability of GC 
cells in vitro and in vivo. MELK knockdown also led 
to alterations in the levels of epithelial mesenchymal 
transition (EMT)-associated proteins. Furthermore, 
in GC patient-derived xenograft models, targeted 
treatment with OTSSP167 showed anticancer effects. 
These results suggest that MELK may be a promising 
target for GC treatment.
In conclusion, our results from generating genome 
wide DNA copy number profiles in GC cell lines and 
validation in primary gastric adenocarcinoma spe-
cimens revealed genomic aberrations redundancies, 
indicating that the cell lines retain the gross genomic 
architecture of primary tumors. Moreover, the cha-
racterization of a small gained region at 9p13.3 in GC 
cell lines and primary gastric adenocarcinoma samples 
revealed MELK as a candidate target gene this region 
that may possibly be linked to the development of GC. 
Therefore, we hypothesize that the copy number gain 
of MELK may be a mechanism of gene overexpression 
Figure 1  9p13 amplification by fluorescence in situ hybridization analysis in ACP02 (A), ACP03 (B) and AGP01 (C) cell lines. Magnification of × 60.
A B C
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and may represent an interesting therapeutic target in 
gastric carcinogenesis. 
COMMENTS
Background
Despite alterations in DNA copy number is one of the key hallmarks of 
carcinogenesis, the chromosomal regions with frequent gain and loss are 
still poorly defined in gastric cancer. The characterization of a small gain or 
loss region in gastric cancer cell lines and primary gastric adenocarcinoma 
samples could reveal a candidate target gene that may possibly be linked to the 
development of gastric cancer. 
Research frontiers
DNA copy number profiles in gastric cancer cell lines and validation in 
primary gastric adenocarcinoma specimens revealed genomic aberrations 
redundancies, indicating that the cell lines retain the gross genomic architecture 
of primary tumors. Moreover, the characterization of a small gained region at 
9p13.3 in gastric cancer cell lines and primary gastric adenocarcinoma samples 
revealed MELK as a candidate target gene that is possibly related to the 
development of gastric cancer. 
Innovations and breakthroughs
Several studies in the literature have correlated gene copy number alterations 
of 9p13 region. A study described a small amplicon at 9p13.3 in prostate cancer 
cell lines and validated IL11RA copy number gain in 75% (15/20) of prostate 
tumors. However, this is the first time that the copy number gain of the MELK 
gene was described in tumor. Furthermore, in gastric cancer patient-derived 
xenograft models, targeted treatment with OTSSP167 (a MELK inhibitor) 
showed anticancer effects. These results suggest that MELK may be a 
promising target for gastric cancer treatment.
Applications
The authors suggested that the copy number gain of MELK may be a 
mechanism of gene overexpression and may represent an interesting 
therapeutic target in gastric carcinogenesis in the future.
Terminology
Copy number variation (CNV) is a type of structural variation characterized by 
duplication or deletion of sections of the genome, which in turn can result in 
phenotypic alterations. Array comparative genomic hybridization (aCGH) is a 
technology developed for a high-resolution evaluation of DNA copy number 
alterations associated with chromosome abnormalities.
Peer-review
The authors tried to identify common copy number alterations by using 
chromosomal comparative genome hybridization and array comparative 
genome hybridization in four gastric cancer cell lines. They concluded MELK as 
a candidate target gene that is possibly related to the development of gastric 
cancer.
REFERENCES
1 Globocan 2012. Cancer Incidence and Mortality Worldwide: 
IARC CancerBase No. 11. International Agency for Research on 
Cancer; 2013. Lyon, France. 2013. Available from: URL: http://
globocan.iarc.fr
2 Lauren P. The two histological main types of gastric carcinoma: 
diffuse and so-called intestinal-type carcinoma. An attempt at a 
histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 
31-49 [PMID: 14320675]
3 Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães 
AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M. 
C-MYC locus amplification as metastasis predictor in intestinal-
type gastric adenocarcinomas: CGH study in Brazil. Anticancer 
Res 2006; 26: 2909-2914 [PMID: 16886612]
4 Calcagno DQ, Leal MF, Taken SS, Assumpção PP, Demachki S, 
Smith Mde A, Burbano RR. Aneuploidy of chromosome 8 and 
C-MYC amplification in individuals from northern Brazil with 
gastric adenocarcinoma. Anticancer Res 2005; 25: 4069-4074 
[PMID: 16309200]
5 Calcagno DQ, Guimarães AC, Leal MF, Seabra AD, Khayat AS, 
Pontes TB, Assumpção PP, De Arruda Cardoso Smith M, Burbano 
RR. MYC insertions in diffuse-type gastric adenocarcinoma. 
Anticancer Res 2009; 29: 2479-2483 [PMID: 19596917]
6 Panani AD. Cytogenetic and molecular aspects of gastric cancer: 
clinical implications. Cancer Lett 2008; 266: 99-115 [PMID: 
18381231 DOI: 10.1016/j.canlet.2008.02.053]
7 Koo SH, Kwon KC, Shin SY, Jeon YM, Park JW, Kim SH, Noh 
SM. Genetic alterations of gastric cancer: comparative genomic 
hybridization and fluorescence In situ hybridization studies. 
Cancer Genet Cytogenet 2000; 117: 97-103 [PMID: 10704677 
DOI: 10.1016/S0165-4608(99)00152-1]
8 Wu MS, Chang MC, Huang SP, Tseng CC, Sheu JC, Lin YW, 
Shun CT, Lin MT, Lin JT. Correlation of histologic subtypes 
and replication error phenotype with comparative genomic 
hybridization in gastric cancer. Genes Chromosomes Cancer 2001; 
30: 80-86 [PMID: 11107179 DOI: 10.1002/1098-2264(2000)9999:
9999<::AID-GCC1062>3.0.CO;2-R]
9 Kimura Y, Noguchi T, Kawahara K, Kashima K, Daa T, 
Yokoyama S. Genetic alterations in 102 primary gastric cancers 
by comparative genomic hybridization: gain of 20q and loss of 
18q are associated with tumor progression. Mod Pathol 2004; 17: 
1328-1337 [PMID: 15154013 DOI: 10.1038/modpathol.3800180]
10 Takeno SS, Leal MF, Lisboa LC, Lipay MV, Khayat AS, 
Assumpção PP, Burbano RR, Smith Mde A. Genomic alterations in 
diffuse-type gastric cancer as shown by high-resolution comparative 
genomic hybridization. Cancer Genet Cytogenet 2009; 190: 1-7 
[PMID: 19264226 DOI: 10.1016/j.cancergencyto.2008.09.007]
11 Seabra AD, Araújo TM, Mello Junior FA, Di Felipe Ávila 
Alcântara D, De Barros AP, De Assumpção PP, Montenegro RC, 
Guimarães AC, Demachki S, Burbano RM, Khayat AS. High-
density array comparative genomic hybridization detects novel 
copy number alterations in gastric adenocarcinoma. Anticancer Res 
2014; 34: 6405-6415 [PMID: 25368240]
12 Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, 
Demachki S, Assumpção PP, Faria MH, Rabenhorst SH, Ferreira 
MV, de Arruda Cardoso Smith M, Burbano RR. Interrelationship 
between chromosome 8 aneuploidy, C-MYC amplification 
and increased expression in individuals from northern Brazil 
with gastric adenocarcinoma. World J Gastroenterol 2006; 12: 
6207-6211 [PMID: 17036397 DOI: 10.3748/WJG.v12.i38.6207]
13 Calcagno DQ, Freitas VM, Leal MF, de Souza CR, Demachki 
S, Montenegro R, Assumpção PP, Khayat AS, Smith Mde A, dos 
Santos AK, Burbano RR. MYC, FBXW7 and TP53 copy number 
variation and expression in gastric cancer. BMC Gastroenterol 
2013; 13: 141 [PMID: 24053468 DOI: 10.1186/1471-230X-13-141]
14 de Souza CR, Leal MF, Calcagno DQ, Costa Sozinho EK, Borges 
Bdo N, Montenegro RC, Dos Santos AK, Dos Santos SE, Ribeiro 
HF, Assumpção PP, de Arruda Cardoso Smith M, Burbano RR. 
MYC deregulation in gastric cancer and its clinicopathological 
implications. PLoS One 2013; 8: e64420 [PMID: 23717612 DOI: 
10.1371/journal.pone.0064420]
15 Costa Raiol LC, Figueira Silva EC, Mendes da Fonseca D, Leal 
MF, Guimarães AC, Calcagno DQ, Khayat AS, Assumpção PP, de 
Arruda Cardoso Smith M, Burbano RR. Interrelationship between 
MYC gene numerical aberrations and protein expression in 
individuals from northern Brazil with early gastric adenocarcinoma. 
Cancer Genet Cytogenet 2008; 181: 31-35 [PMID: 18262050 DOI: 
10.1016/j.cancergencyto.2007.10.011]
16 Liang L, Fang JY, Xu J. Gastric cancer and gene copy number 
variation: emerging cancer drivers for targeted therapy. Oncogene 
2016; 35: 1475-1482 [PMID: 26073079]
17 Leal MF, Martins do Nascimento JL, da Silva CE, Vita Lamarão 
MF, Calcagno DQ, Khayat AS, Assumpção PP, Cabral IR, de 
Arruda Cardoso Smith M, Burbano RR. Establishment and 
 COMMENTS
Calcagno DQ et al . IL11RA and MELK  amplification in GC
9513 November 21, 2016|Volume 22|Issue 43|WJG|www.wjgnet.com
conventional cytogenetic characterization of three gastric cancer 
cell lines. Cancer Genet Cytogenet 2009; 195: 85-91 [PMID: 
19837275 DOI: 10.1016/j.cancergencyto.2009.04.020]
18 Leal MF, Calcagno DQ, Borges da Costa Jde F, Silva TC, Khayat 
AS, Chen ES, Assumpção PP, de Arruda Cardoso Smith M, 
Burbano RR. MYC, TP53, and chromosome 17 copy-number 
alterations in multiple gastric cancer cell lines and in their parental 
primary tumors. J Biomed Biotechnol 2011; 2011: 631268 [PMID: 
21528007 DOI: 10.1155/2011/631268]
19 Ribeiro HF, Alcântara DF, Matos LA, Sousa JM, Leal MF, Smith 
MA, Burbano RR, Bahia MO. Cytogenetic characterization and 
evaluation of c-MYC gene amplification in PG100, a new Brazilian 
gastric cancer cell line. Braz J Med Biol Res 2010; 43: 717-721 
[PMID: 20658094 DOI: 10.1590/S0100-879X2010007500068]
20 Lima EM, Rissino JD, Harada ML, Assumpção PP, Demachki 
S, Guimarães AC, Casartelli C, Smith MA, Burbano RR. 
Conventional cytogenetic characterization of a new cell line, 
ACP01, established from a primary human gastric tumor. Braz J 
Med Biol Res 2004; 37: 1831-1838 [PMID: 15558189]
21 Batista dos Santos SE, Rodrigues JD, Ribeiro-dos-Santos AK, 
Zago MA. Differential contribution of indigenous men and women 
to the formation of an urban population in the Amazon region as 
revealed by mtDNA and Y-DNA. Am J Phys Anthropol 1999; 109: 
175-180 [PMID: 10378456 DOI: 10.1002/(SICI)1096-8644(19990
6)109]
22 Kulikowski LD, Bellucco FT, Nogueira SI, Christofolini DM, 
Smith Mde A, de Mello CB, Brunoni D, Melaragno MI. Pure 
duplication 1q41-qter: further delineation of trisomy 1q syndromes. 
Am J Med Genet A 2008; 146A: 2663-2667 [PMID: 18798309 
DOI: 10.1002/ajmg.a.32510]
23 Sireteanu A, Covic M, Gorduza EV. [Array CGH: technical 
considerations and applications]. Rev Med Chir Soc Med Nat Iasi 
2012; 116: 545-551 [PMID: 23077951]
24 Kamradt J, Jung V, Wahrheit K, Tolosi L, Rahnenfuehrer 
J, Schilling M, Walker R, Davis S, Stoeckle M, Meltzer P, 
Wullich B. Detection of novel amplicons in prostate cancer by 
comprehensive genomic profiling of prostate cancer cell lines 
using oligonucleotide-based arrayCGH. PLoS One 2007; 2: e769 
[PMID: 17712417 DOI: 10.1371/journal.pone.0000769]
25 Knuutila S, Aalto Y, Autio K, Björkqvist AM, El-Rifai W, 
Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy 
ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M, 
Varis A, Wasenius VM, Wolf M, Zhu Y. DNA copy number losses 
in human neoplasms. Am J Pathol 1999; 155: 683-694 [PMID: 
10487825 DOI: 10.1016/S0002-9440(10)65166-8]
26 Nessling M, Solinas-Toldo S, Wilgenbus KK, Borchard F, Lichter 
P. Mapping of chromosomal imbalances in gastric adenocarcinoma 
revealed amplified protooncogenes MYCN, MET, WNT2, and 
ERBB2. Genes Chromosomes Cancer 1998; 23: 307-316 [PMID: 
9824203 DOI: 10.1002/(SICI)1098-2264(199812)23:4<307::AID-
GCC5>3.0.CO;2-#]
27 Kang JU, Kang JJ, Kwon KC, Park JW, Jeong TE, Noh SM, Koo 
SH. Genetic alterations in primary gastric carcinomas correlated 
with clinicopathological variables by array comparative genomic 
hybridization. J Korean Med Sci 2006; 21: 656-665 [PMID: 
16891809 DOI: 10.3346/jkms.2006.21.4.656]
28 Zhu YQ, Zhu ZG, Liu BY, Chen XH, Yin HR, Wang XH. 
[Chromosomal alterations analyzed by comparative genomic 
hybridization in primary gastric carcinoma]. Zhonghua Wei Chang 
Wai Ke Za Zhi 2007; 10: 160-164 [PMID: 17380459]
29 Fan B, Dachrut S, Coral H, Yuen ST, Chu KM, Law S, Zhang L, Ji 
J, Leung SY, Chen X. Integration of DNA copy number alterations 
and transcriptional expression analysis in human gastric cancer. 
PLoS One 2012; 7: e29824 [PMID: 22539939 DOI: 10.1371/
journal.pone.0029824]
30 Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, 
Imamura M, Sugano S, Nakamura Y, Inazawa J. Identification of 
a novel gene, GASC1, within an amplicon at 9p23-24 frequently 
detected in esophageal cancer cell lines. Cancer Res 2000; 60: 
4735-4739 [PMID: 10987278]
31 Italiano A, Attias R, Aurias A, Pérot G, Burel-Vandenbos F, Otto 
J, Venissac N, Pedeutour F. Molecular cytogenetic characterization 
of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere 
and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer 
Genet Cytogenet 2006; 167: 122-130 [PMID: 16737911 DOI: 
10.1016/j.cancergencyto.2006.01.004]
32 Wu J, Liu S, Liu G, Dombkowski A, Abrams J, Martin-Trevino 
R, Wicha MS, Ethier SP, Yang ZQ. Identification and functional 
analysis of 9p24 amplified genes in human breast cancer. 
Oncogene 2012; 31: 333-341 [PMID: 21666724 DOI: 10.1038/
onc.2011.227]
33 Towle R, Tsui IF, Zhu Y, MacLellan S, Poh CF, Garnis C. 
Recurring DNA copy number gain at chromosome 9p13 plays 
a role in the activation of multiple candidate oncogenes in 
progressing oral premalignant lesions. Cancer Med 2014; 3: 
1170-1184 [PMID: 25060540 DOI: 10.1002/cam4.307]
34 Sarhadi VK, Lahti L, Scheinin I, Ellonen P, Kettunen E, Serra 
M, Scotlandi K, Picci P, Knuutila S. Copy number alterations and 
neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and 
PAX5 at 9p in different neoplasias. Genes Chromosomes Cancer 
2014; 53: 579-588 [PMID: 24664538 DOI: 10.1002/gcc.22168]
35 Campbell CL, Jiang Z, Savarese DM, Savarese TM. Increased 
expression of the interleukin-11 receptor and evidence of STAT3 
activation in prostate carcinoma. Am J Pathol 2001; 158: 25-32 
[PMID: 11141475 DOI: 10.1016/S0002-9440(10)63940-5]
36 Kiessling S, Muller-Newen G, Leeb SN, Hausmann M, Rath HC, 
Strater J, Spottl T, Schlottmann K, Grossmann J, Montero-Julian 
FA, Scholmerich J, Andus T, Buschauer A, Heinrich PC, Rogler G. 
Functional expression of the interleukin-11 receptor alpha-chain 
and evidence of antiapoptotic effects in human colonic epithelial 
cells. J Biol Chem 2004; 279: 10304-10315 [PMID: 14701802 
DOI: 10.1074/jbc.M312757200]
37 Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini 
R, Arap W. Combinatorial screenings in patients: the interleukin-11 
receptor alpha as a candidate target in the progression of human 
prostate cancer. Cancer Res 2004; 64: 435-439 [PMID: 14744752]
38 Hanavadi S, Martin TA, Watkins G, Mansel RE, Jiang WG. 
Expression of interleukin 11 and its receptor and their prognostic 
value in human breast cancer. Ann Surg Oncol 2006; 13: 802-808 
[PMID: 16614887 DOI: 10.1245/ASO.2006.05.028]
39 Nakayama T, Yoshizaki A, Izumida S, Suehiro T, Miura S, 
Uemura T, Yakata Y, Shichijo K, Yamashita S, Sekin I. Expression 
of interleukin-11 (IL-11) and IL-11 receptor alpha in human gastric 
carcinoma and IL-11 upregulates the invasive activity of human 
gastric carcinoma cells. Int J Oncol 2007; 30: 825-833 [PMID: 
17332920 DOI: 10.3892/ijo.30.4.825]
40 Lewis VO, Ozawa MG, Deavers MT, Wang G, Shintani T, Arap 
W, Pasqualini R. The interleukin-11 receptor alpha as a candidate 
ligand-directed target in osteosarcoma: consistent data from cell 
lines, orthotopic models, and human tumor samples. Cancer Res 
2009; 69: 1995-1999 [PMID: 19244100 DOI: 10.1158/0008-5472.
CAN-08-4845]
41 Liu T, Ma Q, Zhang Y, Ke S, Yan K, Chen X, Wen Y, Fan Q, 
Qiu X. Interleukin-11 receptor α is overexpressed in human 
osteosarcoma, and near-infrared-labeled IL-11Rα imaging agent 
could detect osteosarcoma in mouse tumor xenografts. Tumour 
Biol 2015; 36: 2369-2375 [PMID: 25524575 DOI: 10.1007/
s13277-014-2844-6]
42 Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner 
KJ, Dorner AJ. Hematopoietic, immunomodulatory and epithelial 
effects of interleukin-11. Leukemia 1999; 13: 1307-1315 [PMID: 
10482979]
43 Teramura M, Kobayashi S, Yoshinaga K, Iwabe K, Mizoguchi H. 
Effect of interleukin 11 on normal and pathological thrombopoiesis. 
Cancer Chemother Pharmacol 1996; 38 Suppl: S99-S102 [PMID: 
8765427 DOI: 10.1007/s002800051048]
44 Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, 
Cohen T, Camargo AA, Kosoy A, Carlotti CG, Toledo S, Moreira-
Filho CA, Zago MA, Simpson AJ, Caballero OL. Maternal 
embryonic leucine zipper kinase transcript abundance correlates 
Calcagno DQ et al . IL11RA and MELK  amplification in GC
9514 November 21, 2016|Volume 22|Issue 43|WJG|www.wjgnet.com
with malignancy grade in human astrocytomas. Int J Cancer 2008; 
122: 807-815 [PMID: 17960622 DOI: 10.1002/ijc.23189]
45 Ganguly R, Hong CS, Smith LG, Kornblum HI, Nakano I. 
Maternal embryonic leucine zipper kinase: key kinase for stem 
cell phenotype in glioma and other cancers. Mol Cancer Ther 
2014; 13: 1393-1398 [PMID: 24795222 DOI: 10.1158/1535-7163.
MCT-13-0764]
46 Ryu B, Kim DS, Deluca AM, Alani RM. Comprehensive 
expression profiling of tumor cell lines identifies molecular 
signatures of melanoma progression. PLoS One 2007; 2: e594 
[PMID: 17611626 DOI: 10.1371/journal.pone.0000594]
47 Pickard MR, Green AR, Ellis IO, Caldas C, Hedge VL, Mourtada-
Maarabouni M, Williams GT. Dysregulated expression of Fau and 
MELK is associated with poor prognosis in breast cancer. Breast 
Cancer Res 2009; 11: R60 [PMID: 19671159 DOI: 10.1186/
bcr2350]
48 Kuner R, Fälth M, Pressinotti NC, Brase JC, Puig SB, Metzger 
J, Gade S, Schäfer G, Bartsch G, Steiner E, Klocker H, Sültmann 
H. The maternal embryonic leucine zipper kinase (MELK) is 
upregulated in high-grade prostate cancer. J Mol Med (Berl) 2013; 
91: 237-248 [PMID: 22945237 DOI: 10.1007/s00109-012-0949-1]
49 Du T, Qu Y, Li J, Li H, Su L, Zhou Q, Yan M, Li C, Zhu Z, Liu B. 
Maternal embryonic leucine zipper kinase enhances gastric cancer 
progression via the FAK/Paxillin pathway. Mol Cancer 2014; 13: 
100 [PMID: 24885567 DOI: 10.1186/1476-4598-13-100]
50 Gray D, Jubb AM, Hogue D, Dowd P, Kljavin N, Yi S, Bai 
W, Frantz G, Zhang Z, Koeppen H, de Sauvage FJ, Davis DP. 
Maternal embryonic leucine zipper kinase/murine protein serine-
threonine kinase 38 is a promising therapeutic target for multiple 
cancers. Cancer Res 2005; 65: 9751-9761 [PMID: 16266996 DOI: 
10.1158/0008-5472.CAN-04-4531]
51 Chung S, Nakamura Y. MELK inhibitor, novel molecular targeted 
therapeutics for human cancer stem cells. Cell Cycle 2013; 12: 
1655-1656 [PMID: 23673321 DOI: 10.4161/cc.24988]
52 Minata M, Gu C, Joshi K, Nakano-Okuno M, Hong C, Nguyen 
CH, Kornblum HI, Molla A, Nakano I. Multi-kinase inhibitor C1 
triggers mitotic catastrophe of glioma stem cells mainly through 
MELK kinase inhibition. PLoS One 2014; 9: e92546 [PMID: 
24739874 DOI: 10.1371/journal.pone.0092546]
53 Ganguly R, Mohyeldin A, Thiel J, Kornblum HI, Beullens M, 
Nakano I. MELK-a conserved kinase: functions, signaling, cancer, 
and controversy. Clin Transl Med 2015; 4: 11 [PMID: 25852826 
DOI: 10.1186/s40169-014-0045-y]
54 Li S, Li Z, Guo T, Xing XF, Cheng X, Du H, Wen XZ, Ji JF. 
Maternal embryonic leucine zipper kinase serves as a poor 
prognosis marker and therapeutic target in gastric cancer. 
Oncotarget 2016; 7: 6266-6280 [PMID: 26701722 DOI: 10.18632/
oncotarget.6673]
P- Reviewer: Kupeli S    S- Editor: Qi Y    L- Editor: A 
E- Editor: Wang CH 
Calcagno DQ et al . IL11RA and MELK  amplification in GC
                                      © 2016 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
4   3
